Baader Bank Aktiengesellschaft Buys 7,328 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Baader Bank Aktiengesellschaft raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 208.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,844 shares of the biopharmaceutical company’s stock after purchasing an additional 7,328 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Gilead Sciences were worth $1,002,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $25,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences during the 4th quarter worth about $29,000. Valued Wealth Advisors LLC grew its position in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares in the last quarter. Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at about $33,000. Finally, Friedenthal Financial purchased a new stake in Gilead Sciences during the third quarter worth approximately $50,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Robert W. Baird boosted their price objective on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Bank of America restated a “buy” rating and issued a $109.00 target price on shares of Gilead Sciences in a research note on Tuesday, December 10th. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Barclays raised their price objective on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Trading Up 1.9 %

Shares of GILD stock opened at $95.59 on Thursday. The stock has a market capitalization of $119.13 billion, a price-to-earnings ratio of 1,062.11, a PEG ratio of 1.31 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The company’s fifty day simple moving average is $92.00 and its two-hundred day simple moving average is $85.44. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the firm earned $2.29 earnings per share. Gilead Sciences’s revenue was up 7.0% on a year-over-year basis. As a group, analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This represents a 67.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 456,234 shares of company stock valued at $42,130,461. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.